Extension of the therapeutic spectrum in castration-resistant prostate cancer: Osteoclast inhibition with denosumab

Johannes M. Wolff,Hans Peter Schmid

Extension of the therapeutic spectrum in castration-resistant prostate cancer: Osteoclast inhibition with denosumab

2012

Johannes M. Wolff
Hans Peter Schmid

Denosumab is a human monoclonal antibody (IgG2) that binds to RANK ligand (RANKL). It reduces osteoclasts and thereby decreases bone resorption and cancer-induced bone destruction.

Keywords:

Cancer research
RANK Ligand
Bone resorption
Denosumab
RANKL
Prostate cancer
Osteoclast
Castration
Monoclonal antibody
Medicine
Bioinformatics
castration resistant

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations